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Venous thromboembolism (VTE) is an important and potentially
fatal complication in patients with malignant disease. Increasingly,
VTE is recognised to affect not only patients undergoing surgical
intervention for the management of their cancer but also those
receiving chemotherapy, including ambulatory patients. The
extent to which thrombosis complicates the natural history of
different populations of patients with malignant disease is poorly
understood. The risk factors associated with the development of
thromboembolic complications include stage of disease, anatomi-
cal site of tumour, and tumour histology, in addition to commonly
recognised risk factors for the development of thromboembolism,
such as advanced stage, obesity, and a history of VTE.
The type of therapeutic intervention also has an important
impact on the risk for VTE. It is well recognised that patients
undergoing laparotomy for intra-abdominal or pelvic malignancy
are at heightened risk for the development of postoperative VTE.
For those receiving cytotoxic chemotherapy, the nature of
cytotoxic therapy may influence risk for VTE. Increasingly,
however, there is also recognition of the importance of biological
anticancer therapies in heightening the risk for thrombosis. This
multimodal interaction between patient and therapeutic factors
makes identification of patients at risk for thrombosis difficult, but
various methods, including risk-assessment scores and the
development of biomarkers to predict those at risk for thrombosis,
are currently under development.
It is well established that pharmacological thromboprophylaxis
is warranted in the majority of patients with cancer undergoing
surgery. At present, low-dose unfractionated heparin or low-
molecular-weight heparins (LMWHs) are the thromboprophylactic
modalities of choice. In general, prophylaxis is usually provided
for the duration of hospital stay, but – in some cases – may be
extended for patients with an increased risk for thromboembolic
disease after hospital discharge.
For patients undergoing medical management of their cancer
and who are hospitalised with an acute medical condition, we
recommended thromboprophylaxis with LMWHs for the duration
of hospital stay. Considerable controversy exists regarding the
benefits of extended prophylaxis on an outpatient basis for
ambulant patients receiving chemotherapy, as guidelines currently
do not recommend routine prophylaxis for this group. For those
patients with established thromboembolism, long-term therapy
with an LMWH offers important advantages in reducing the
frequency of recurrent thromboembolic disease compared with
those receiving standard anticoagulant therapy for the prevention
of recurrent thromboembolism with a vitamin K antagonist.
Intriguingly, exposure to LMWHs has been suggested to prolong
survival in patients with malignant disease. Early studies – many of
which have had methodological flaws – suggested that LMWHs
may indeed prolong survival in patients with cancer. Ongoing
studies will provide further information regarding which patient
populations benefit most from exposure to LMWHs in terms of
survival.
This supplement provides a broad-based review of current
topics in the prevention and treatment of VTE, as well as the
impact of treatment with anticoagulants on prognosis and survival
in patients with cancer, with particular focus on the management
of patients in the United Kingdom. An expert panel was convened
in London to review data related to the pathophysiology,
epidemiology, prevention, and treatment of VTE, and the role of
antithrombotic therapy in the survival of patients with cancer. The
panel also reviewed international guidelines for the prophylaxis
and treatment of VTE to assess and interpret this information in
the context of current practices in the United Kingdom. Each
article in this supplement consists of a data review based on the
presentations given at the meeting, a transcript of the discussions
held around each topic, and – finally – a brief consensus statement
discussing treatment recommendations and research priorities for
the future. These articles, when taken together, represent the state
of the art in the treatment and prevention of VTE in cancer
patients, and aim to improve clinical practice in the United
Kingdom for this important patient population.
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